Gatifloxacin hydrochloride

SKU: orb1298979

Description

Gatifloxacin hydrochloride is a fourth-generation fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV. It is widely used in research for studying antibacterial mechanisms and efficacy in both in vitro and in vivo experimental models.

Research Area

Infectious Disease & Virology, Molecular Biology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 121577-32-0
• MW: 411.86
• Purity: 99.85% (May vary between batches)
• Formula: C₁₉H₂₃ClFN₃O₄
• SMILES: Cl.COc1c(N2CCNC(C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1
• Target: Topoisomerase|||Antibiotic|||Antibacterial
• Solubility: H2O:10 mg/mL (24.28 mM);DMSO:4.12 mg/mL (10 mM)

Bioactivity

• Target IC50:
  Topo II:36.7 μM
• In Vivo:
  All eyes showed evidence of infection by 48 hours postinoculation with 36 of 41 eyes (87.8%) exhibiting moderate-to-severe keratitis. All eyes exhibited corneal healing by day 15, with no significant differences among groups. Three of 4 groups receiving gatifloxacin tended to have smaller fluorescein retention area scores than did the ciprofloxacin group. No eyes tested positive for Pseudomonas at the end of the study. No corneal precipitates were found following as many as 48 doses/day of gatifloxacin.
  Read more...
• Animal Research:
  Heptanol-induced corneal ulcers in New Zealand White rabbits (n = 41; 8 females/group) were inoculated with 10(6) CFU of Pseudomonas aeruginosa. Gatifloxacin 0.3% dosing varied among 4 groups with frequencies of 16-48 doses/day (days 1-2), 3-16 doses/day (days 3-7), and maintenance dosing of 3-4 doses/day (days 8-22). Ciprofloxacin 0.3% was administered as labeled for corneal ulcers, with 44 doses on day 1, 16 doses on day 2, and 4 doses/day on days 3-21
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, PD 135432, PD135432, PD-135432, PD135432 (hydrochloride), N. brasiliensis, Inhibitor, Gatifloxacin Hydrochloride, Gatifloxacin, Gatifloxacin hydrochloride, hypoglycemia, hyperglycemia, BMS206584, BMS-206584, BMS-206584 (hydrochloride), BMS 206584, Antibiotic, Bacterial, AM 1155, AM1155, AM-1155, AM-1155 (hydrochloride), actinomycetoma, diabetic, E. coli,?Pseudomonas aeruginosa,?Micrococcus luteus, conjunctivitis, S. aureus, Topoisomerase

Compound Identifiers

PubChem CID

17956339